Tiroxil® Line

Food supplements for the management of subclinical thyroid disorders. Nine clinical studies demonstrate, among other results, TSH reductions and autoimmunity control in patients with subclinical hypothyroidism after 6 months of treatment using the 4.0 formulation. One clinical trial demonstrates efficacy of the 0.4 formulation in subclinical hyperthyroidism, while one clinical trial is ongoing. Strong scientific backgrounds support both the D formulation, for patients with subclinical hypothyroidism over 50, and Iodact which targets iodine deficiency patients, especially in obese patients, those with borderline FT4 levels, or patients with goiter.